Mutants of streptococcal toxin a and methods of use
AssigneeRegents of the University of Minnesota
InventorsPATRICK M SCHLIEVERT, MANUELA ROGGIANI, JENNIFER STOEHR, DOUGLAS OHLENDORF
Life of this patent
Estimating the term…
Abstract
This invention is directed to mutant SPE-A toxins or fragments thereof, vaccine and pharmaceutical compositions, and methods of using the vaccine and pharmaceutical compositions. The preferred SPE-A toxin has at least one amino acid change and is substantially non-lethal compared with the wild type SPE-A toxin. The mutant SPE-A toxins can form vaccine compositions useful to protect animals against the biological activities of wild type SPE-A toxin.
Claims23
A mutant SPE-A toxin or fragment thereof, the mutant SPE-A toxin comprising one to six amino acid substitutions and being substantially nonlethal compared with a protein substantially corresponding to wild type SPE-A toxin;
- wherein at least one of the substituted amino acids is positioned in N-terminal alpha helix 3, in domain B beta strand 1, in domain B beta strand 2, in domain B beta strand 3, in domain A beta strand 6, in domain A beta strand 8, in domain A beta strand 9, in domain A beta strand 10, or is a cysteine.
A mutant SPE-A toxin or fragment thereof, wherein the mutant has at least two amino acid changes and is substantially nonlethal compared with a protein substantially corresponding to wild type SPE-A toxin.
A stably transformed host cell comprising a DNA sequence according to claim 29.
Dependencies are inferred from the claim text.